Global Allergic Rhinitis Drugs Market to 2023: New Therapies is Expected to Drive Growth in the Market

Dublin, Jan. 16, 2019 (GLOBE NEWSWIRE) -- The "Global Allergic Rhinitis Drugs Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The allergic rhinitis drugs market will register a CAGR of close to 4% by 2023.

The rise in R&D of new therapies is expected to drive growth in the market. There has been an increase in the prevalence of allergic diseases globally. If these diseases are not managed at an early stage, allergic diseases such as rhinitis can increase the risk of asthma in patients. Several organizations are trying to understand the pathogenesis of these diseases.

Market Overview

Increasing prevalence of allergic rhinitis

The increase in the prevalence of allergic rhinitis is expected to increase the pool of patients as well as the consumption of medicine. This worldwide increase in the incidence of allergic rhinitis is likely to drive growth of the allergic rhinitis drugs market.

Competition from generics

The increase in competition from generics is expected to adversely affect the market during the forecast period.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Sanofi and Stallergenes Greer, the competitive environment is quite intense. Factors such as the increase in the prevalence of allergic rhinitis and the rise in R&D of new therapies, will provide considerable growth opportunities to allergic rhinitis drugs manufactures.

ALK-Abell, GlaxoSmithKline, Merck, Sanofi, and Stallergenes Greer are some of the major companies covered in this report.

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 04: PIPELINE ANALYSIS

• Pipeline analysis

PART 05: MARKET SIZING

• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 07: MARKET SEGMENTATION BY PRODUCT

• Comparison by product
• Antihistamines
• Intranasal corticosteroids
• Immunotherapies
• Others
  
• Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

• Geographic comparison
• Key leading countries
• Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

• Market drivers
• Market challenges

PART 12: MARKET TRENDS

• Market trends

PART 13: VENDOR LANDSCAPE

• Overview
• Landscape disruption

PART 14: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• ALK-Abell
• GlaxoSmithKline
• Merck
• Sanofi
• Stallergenes Greer

PART 15: APPENDIX

For more information about this report visit https://www.researchandmarkets.com/research/9f9rrx/global_allergic?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Allergy Drugs